Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion

Jing Wang, Natalie W. Pursell, Maria Elena S. Samson, Ruzanna Atoyan, Anna W. Ma, Abdelkader Selmi, Wanlu Xu, Xiong Cai, Maurizio Voi, Pierre Savagner, Cheng-Jung Lai

Mol Cancer Ther (2013) 12 (6): 925–936.

https://doi.org/10.1158/1535-7163.MCT-12-1045

Published: 09 June 2013

View article titled, Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion

Includes: Supplementary data

Journal Articles

Abstract C179: Discovery of a series of novel PARP-1 inhibitors with potent in vitro and in vivo activity.

Sui Xiong Cai, Qingbing Xu, Lizhen Wu, Lijun Liu, Yangzhen Jiang, Qingli Bao, Guoxiang Wang, Xiuyan Zhang, Feng Yin, Chengyun Gu, Xiuhua Hu, Xiaozhu Wang, Sishun Kang, Shengzhi Chen, Ye Edward Tian

Mol Cancer Ther (2011) 10 (11_Supplement): C179.

https://doi.org/10.1158/1535-7163.TARG-11-C179

Published: 12 November 2011

View article titled, Abstract C179: Discovery of a series of novel PARP-1 inhibitors with potent in vitro and in vivo activity.

Journal Articles

Abstract C70: Antitumor activity of CUDC-907, a single small molecule inhibitor that targets both PI3K and HDAC, in hematologic cancer models.

Rudi Bao, Dagong Wang, Hui Qu, Jing Wang, Ruzanna Atoyan, Guang-Xin Xu, Ling Yin, Brian Zifcak, Mylissa Borek, Maria Samson, Anna Ma, Steven DellaRocca, Hai-Xiao Zhai, Cheng-Jung Lai, Carmen Pepicelli, Xiong Cai, Changgeng Qian

Mol Cancer Ther (2011) 10 (11_Supplement): C70.

https://doi.org/10.1158/1535-7163.TARG-11-C70

Published: 12 November 2011

View article titled, Abstract C70: Antitumor activity of CUDC-907, a single small molecule inhibitor that targets both PI3K and HDAC, in hematologic cancer models.

Journal Articles

Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non–small cell lung cancer

Rudi Bao, Cheng-Jung Lai, Da-Gong Wang, Hui Qu, Ling Yin, Brian Zifcak, Xu Tao, Jing Wang, Ruzanna Atoyan, Maria Samson, Jeffrey Forrester, Guang-Xin Xu, Steven DellaRocca, Mylissa Borek, Hai-Xiao Zhai, Xiong Cai, Changgeng Qian

Mol Cancer Ther (2009) 8 (12): 3296–3306.

https://doi.org/10.1158/1535-7163.MCT-09-0538

Published: 09 December 2009

View article titled, Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non–small cell lung cancer

Journal Articles

The discovery and mechanism of action of novel tumor-selective and apoptosis-inducing 3,5-diaryl-1,2,4-oxadiazole series using a chemical genetics approach

Katayoun A. Jessen, Nicole M. English, Jean Yu Wang, Sergei Maliartchouk, Shannon P. Archer, Ling Qiu, Regina Brand, Jared Kuemmerle, Han-Zhong Zhang, Kurt Gehlsen, John Drewe, Ben Tseng, Sui Xiong Cai, Shailaja Kasibhatla

Mol Cancer Ther (2005) 4 (5): 761–771.

https://doi.org/10.1158/1535-7163.MCT-04-0333

Published: 16 May 2005

View article titled, The discovery and mechanism of action of novel tumor-selective and apoptosis-inducing 3,5-diaryl-1,2,4-oxadiazole series using a chemical genetics approach

Includes: Supplementary data

Journal Articles

Antivascular and antitumor evaluation of 2-amino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromenes, a novel series of anticancer agents

Henriette Gourdeau, Lorraine Leblond, Bettina Hamelin, Clemence Desputeau, Kelly Dong, Irenej Kianicka, Dominique Custeau, Chantal Boudreau, Lilianne Geerts, Sui-Xiong Cai, John Drewe, Denis Labrecque, Shailaja Kasibhatla, Ben Tseng

Mol Cancer Ther (2004) 3 (11): 1375–1384.

https://doi.org/10.1158/1535-7163.1375.3.11

Published: 01 November 2004

View article titled, Antivascular and antitumor evaluation of 2-amino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromenes, a novel series of anticancer agents

Journal Articles

Discovery and mechanism of action of a novel series of apoptosis inducers with potential vascular targeting activity

Shailaja Kasibhatla, Henriette Gourdeau, Karen Meerovitch, John Drewe, Sanjeeva Reddy, Ling Qiu, Hong Zhang, Frederick Bergeron, David Bouffard, Quan Yang, John Herich, Serge Lamothe, Sui Xiong Cai, Ben Tseng

Mol Cancer Ther (2004) 3 (11): 1365–1374.

https://doi.org/10.1158/1535-7163.1365.3.11

Published: 01 November 2004

View article titled, Discovery and mechanism of action of a novel series of apoptosis inducers with potential vascular targeting activity

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion

Abstract C179: Discovery of a series of novel PARP-1 inhibitors with potent in vitro and in vivo activity.

Abstract C70: Antitumor activity of CUDC-907, a single small molecule inhibitor that targets both PI3K and HDAC, in hematologic cancer models.

Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non–small cell lung cancer

The discovery and mechanism of action of novel tumor-selective and apoptosis-inducing 3,5-diaryl-1,2,4-oxadiazole series using a chemical genetics approach

Antivascular and antitumor evaluation of 2-amino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromenes, a novel series of anticancer agents

Discovery and mechanism of action of a novel series of apoptosis inducers with potential vascular targeting activity

Email alerts

AACR Journals

Resources

AACR Journals
on Social Media

Update search

Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion

Abstract C179: Discovery of a series of novel PARP-1 inhibitors with potent in vitro and in vivo activity.

Abstract C70: Antitumor activity of CUDC-907, a single small molecule inhibitor that targets both PI3K and HDAC, in hematologic cancer models.

Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non–small cell lung cancer

The discovery and mechanism of action of novel tumor-selective and apoptosis-inducing 3,5-diaryl-1,2,4-oxadiazole series using a chemical genetics approach

Antivascular and antitumor evaluation of 2-amino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromenes, a novel series of anticancer agents

Discovery and mechanism of action of a novel series of apoptosis inducers with potential vascular targeting activity

Email alerts

AACR Journals

Resources

AACR Journals on Social Media

This Feature Is Available To Subscribers Only

AACR Journals
on Social Media